Vascular Biogenics (NASDAQ: VBLT) announces its next round of earnings this Monday, November 16. Here is Benzinga's everything-that-matters guide for this Monday's Q3 earnings announcement. Net Income ...

In the annals of botched IPOs, there's the BATS disaster, and there's Facebook's notorious debut, but the train wreck that is Vascular Biogenics' IPO stands alone. The company priced its IPO on Nasdaq ...

After the company released the pricing details of its just-announced common stock offering, shares of Vascular Biogenics (NASDAQ: VBLT), a clinical-stage biotech focused on cancer, fell 18% as of ...

It was the IPO that wasn't: A biotech firm hit the market and traded for six days, only to announce Friday that it wasn't issuing shares after all, thanks to a key investor's failure to follow through ...

Vascular Biogenics Ltd (NASDAQ:VBLT) shares are falling Wednesday after the company announced that the data from its Phase 3 OVAL trial of ofra-vec in platinum-resistant ovarian cancer did not meet ...

Today we look at a small oncology concern headquartered in Israel that will have a poster presentation at the upcoming ASCO conference in Chicago in early June. It is well-funded, has upcoming ...

Vascular Biogenics announced that it is raising $18.75 million from the sale of 2.5 million shares of common stock. That works out to a price of $7.50 per share. The offering is expected to dilute ...